美国Tau Therapeutics www.tautherapeutics.com
研发的T型钙通道阻滞剂米贝拉地尔（mibefradil）用于实体肿瘤的治疗。

Tau Therapeutics is developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type calcium channel blockade with Tau’s drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.

Tau’s first product, mibefradil, has been used extensively in humans and its safety profile is well known. Mibefradil is now entering clinical trials for brain cancer with support from the NCI.

Tau Therapeutics is a private company based in Charlottesville, VA.